Nanopharmaceuticals and NanoBiology: A New Approach to Designing Intelligent Drugs

Nanopharmaceuticals are a new type of drug that consists of ultra-small particles measured in nanometers (a nanometer is one billionth of a meter). These drug-containing particles can be designed to enhance the therapeutic utility of drugs and allow for:

  • the delivery of drugs to specific diseased tissues,
  • the controlled release of therapeutic concentrations of drugs over a short or prolonged period of time, and
  • improved formulations of established therapies.

Nanobiology is an emerging, next-generation approach designed to create new nanopharmaceuticals that more optimally target the root causes of disease. Nanobiology enables more optimally-targeted drugs because it combines an understanding of the complex biological microenvironment of human disease and the latest advances in engineering chemical structures at the nanoscale.

By leveraging this unique nanobiology-based drug development approach, Cerulean is intelligently designing a deep pipeline of novel nanopharmaceuticals which have the potential to achieve cures and improve the lives of patients where it was not previously possible. Cerulean is focused on the therapeutic areas of oncology, autoimmune and inflammatory diseases.